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PCLINICAL RESEARCH Interventional Cardiology
Randomized Trial of Sirolimus-Eluting Stent Versus
Bare-Metal Stent in Acute Myocardial Infarction (SESAMI)
Maurizio Menichelli, MD,* Antonio Parma, MD,* Edoardo Pucci, MD,* Rosario Fiorilli, MD,*
Francesco De Felice, MD,* Marco Nazzaro, MD,* Alessia Giulivi, MD,* Domenico Alborino, MD,*
Arianna Azzellino, PHD,† Roberto Violini, MD*
Rome and Milan, Italy
Objectives To confirm whether sirolimus-eluting stents (SES) safely reduce the incidence of restenosis in patients with
ST-segment elevation acute myocardial infarction compared with bare-metal stents (BMS).
Background In the setting of primary angioplasty, stent restenosis occurs in up to 27% of patients. The introduction of drug-
eluting stents has drastically reduced the incidence of restenosis in clinically stable patients.
Methods We conducted a randomized trial of 320 patients with acute ST-segment elevation myocardial infarction as-
signed to receive SES or BMS. The primary end point was binary restenosis at 1-year angiographic follow-up.
Results At 1 year, the incidence of binary restenosis was lower in the SES group than in the BMS group (9.3% vs. 21.3%,
respectively; p  0.032), as were the rates of target lesion revascularization (4.3% vs. 11.2%; p  0.02), target
vessel revascularization (5% vs. 13.1; p  0.015), major adverse cardiac events (6.8% vs. 16.8%; p  0.005),
and target vessel failure (8.7% vs. 18.7%; p  0.007). The incidence of angiographically documented stent
thrombosis was 1.2% (n  2) in the SES group and 0.6% (n  1) in the BMS group.
Conclusions In patients with acute myocardial infarction, SES are superior to BMS, reducing the incidence of binary resteno-
sis by 56%, target lesion revascularization by 61%, target vessel revascularization by 62%, adverse cardiac
events by 59%, and target vessel failure by 53% at 1 year. (Sirolimus Eluting Stenting in Acute Myocardial
Infarction; http://www.clinicaltrials.gov/ct/show/NCT00288210; NCT00288210) (J Am Coll Cardiol 2007;49:
1924–30) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.081e
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che treatment of acute myocardial infarction (MI) has
volved dramatically in the last decade. Primary coronary
ngioplasty with stent implantation is now considered the
tandard of care. However, in the setting of primary
ngioplasty, the incidence of stent restenosis remains high,
See page 1931
p to 27% (1,2), leading to rehospitalization and increased
ost (3,4). In patients undergoing elective percutaneous
oronary intervention (PCI), the use of drug-eluting stents
as drastically reduced the incidence of restenosis compared
ith bare-metal stents (BMS) in patients with comparable
tent thrombosis (5–9). However, it is not known if
irolimus-eluting stents (SES) increase event-free survival at
id-term follow-up after acute MI. To answer this ques-
ion, we conducted a study in which patients with acute MI
rom the *Division of Interventional Cardiology, San Camillo Hospital, Rome, Italy;
nd the †Politecnico Milano, Milan, Italy.c
Manuscript received October 31, 2006; revised manuscript received January 11,
007, accepted January 16, 2007.ligible for primary angioplasty were randomized to receive
ES or BMS.
ethods
he SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal
tent in Acute Myocardial Infarction) trial is a randomized
rial conducted in a single center where patients with
uspected acute MI are admitted directly to the cardiac
atheterization laboratory. Percutaneous transluminal coro-
ary angioplasty was performed by 6 experienced operators,
ach of whom performs 200 to 250 such elective procedures
nnually. The study was approved by our hospital ethics
ommittee, and all randomized patients gave written in-
ormed consent. The trial was conducted in accordance with
he ethical principles of the Helsinki Declaration regarding
nvestigation in humans.
tudy population. Patients were included if they were18
ears of age, had symptoms of acute MI for 30 min but
12 h, and had 1 mm ST-segment elevation in at least 2
ontiguous leads or left bundle-branch block. The exclusion
riteria were cardiogenic shock (systolic blood pressure 80
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May 15, 2007:1924–30 SES Versus BMS in Acute MIm Hg for 30 min or need for intravenous pressors or
ntra-aortic balloon counterpulsation); a history of bleeding
iathesis, leukopenia, thrombocytopenia, or severe hepatic
r renal dysfunction; noncardiac illness associated with a life
xpectancy of 1 year; left main coronary artery or graft
isease; participation in another study; or inability to give
nformed consent owing to prolonged cardiopulmonary
esuscitation. Excluded patients received clinically appropri-
te treatment.
atheterization and study procedure. The study protocol
ecommended that aspirin (500 mg intravenously) and
eta-blockers (in the absence of contraindications) be ad-
inistered in the emergency room. Patients were then taken
mmediately to the cardiac catheterization laboratory to
ndergo coronary angiography.
Once blood flow was established (spontaneously or by
alloon inflation), the operator determined if the patient
ualified for randomization. The infarct-related vessel had
o be a native coronary artery with a visually estimated
eference diameter 2.5 and 4.0 mm. Sealed sequentially
umbered opaque allocation envelopes were used for ran-
omization. The allocation schedule was based on
omputer-generated random numbers (block size 20). Pa-
ients were assigned in equal numbers to receive SES
Cypher, Cordis, Miami Lakes, Florida) or BMS (BX stent,
ordis) of the same diameter as the reference vessel.
lopidogrel, an inhibitor of adenosine diphosphate–
nduced platelet aggregation, was given as a bolus of 4
ablets immediately after the procedure and was continued
or 1 year in both groups. Dilatation after stent placement
as at the operator’s discretion.
Myocardial perfusion was graded as in the Thrombolysis
n Myocardial Infarction (TIMI) trial; flow grade 3 within
he vessel was considered to be normal (10). The glyco-
rotein IIb/IIIa receptor inhibitor abciximab (ReoPro, Eli
illy, Indianapolis, Indiana; Centocor, Horsham, Pennsyl-
ania) was administered as a 0.25 mg/kg bolus followed by
12-h infusion (0.125 g/kg/min; maximum, 10 g/min)
11–14). If it was not started in the emergency room,
bciximab therapy was initiated in the catheterization lab-
ratory before coronary angiography. The heparin dose was
alculated to achieve an activated clotting time of 200 to
50 s. Plasma levels of creatine kinase-myocardial band and
roponin I were measured in samples obtained at baseline
nd 8 and 24 h after the index procedure.
ngiographic analysis. Cineangiograms were obtained
mmediately after the procedure, according to standard
uidelines. Standard morphologic criteria were used to
haracterize the complexity of the lesions at baseline and to
dentify angiographic complications (15).
Successful stent implantation was defined as 20%
esidual stenosis by visual assessment over the entire stent
ength, with TIMI flow grade 3 and no more than
ational Heart, Lung, and Blood Institute type A
eristent dissection. Angiographic readers were blinded
o the type of stent implanted. The projection that best rhowed the stenosis was used
or all of the analyses. The
ontrast-filled nontapered tip
f the catheter was used for
alibration. Digital angiograms
ere analyzed with an auto-
ated edge-detection system
CAAS II, Pie Medical Imag-
ng, Maastricht, the Nether-
ands) (16). The minimal lumi-
al diameter and extent of
tenosis were measured before
nd after the procedure and at
ollow-up. Binary restenosis
as defined as 50% reduction
f the initial lumen diameter in
he target lesion inside or at the
roximal and distal 5 mm of the
tent.
nd points. The primary end point for the trial was binary
estenosis at the 1-year angiographic follow-up. All serious
linical events, including stent thrombosis, were reviewed by
authors (A.G. and D.A.), who were unaware of stent
ssignment. The secondary end points were target lesion
evascularization (TLR), target vessel revascularization
TVR), major adverse cardiovascular events (MACE), and
arget vessel failure (TVF) at 1 year.
Target lesion revascularization was defined as repeated
CI or bypass grafting of the target vessel driven by clinical
ymptoms of myocardial ischemia, a positive stress test
ttributable to the target vessel, or an in-lesion stenosis
70% of the reference luminal diameter. Target vessel
ailure was defined as the combination of TVR, recurrent
nfarction, and target vessel-related death within 1 year.
einfarction was defined as recurrent ischemic symptoms or
lectrocardiographic changes, accompanied by a creatine
inase level more than twice the upper limit of the normal
ange (and an elevated myocardial band isoform level) or
ore than 50% higher than the previous value during
ospitalization.
To capture all possible adverse events attributable to stent
hrombosis, we used the new Academic Research Consor-
ium definitions for thrombosis. Stent thrombosis was
efined as definite (angiographic confirmation), probable
heart attack attributable to the treated vessel without
ngiographic confirmation), or possible (unexplained sud-
en death not attributed to another cause such as car
ccident or cancer).
tatistical analysis. To determine the effect of SES on
inary restenosis in patients with acute MI, we calculated
hat 160 patients would be required to undergo angio-
raphic follow-up at 1 year. To detect with 90% power a
eduction in the primary end point, using a 2-sided test for
ifferences in independent binomial proportions, we set
ignificance at the 0.025 level, given expected restenosis
Abbreviations
and Acronyms
BMS  bare-metal stents
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stents
TIMI  Thrombolysis In
Myocardial Infarction
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularizationates of 27% (1,2) after BMS and 7% after SES. To
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SES Versus BMS in Acute MI May 15, 2007:1924–30ccommodate patient loss at the angiographic follow-up, we
nrolled 200 patients. To have more information about the
econdary clinical end points (TLR, TVR, MACE, and
VF) at 1 year, we increased this number to 320 patients.
Categoric variables were compared with the likelihood
atio chi-square test or the Fisher exact test. Continuous
ariables are presented as median and interquartile range
nd were compared with 1-way analysis of variance or the
ann-Whitney test; for pairwise analyses, the Wilcoxon
-sample test was used.
Event-free composites during the 1-year follow-up
ere analyzed with the Kaplan-Meier method. Differ-
nces in the 2 event-free curves were analyzed with the
og-rank test; a 2-sided probability of 0.05 was consid-
red to be significant. The treatment groups were com-
ared on an intent-to-treat basis. All statistical tests were
erformed with SPSS for Windows, version 14 (SPSS
nc., Chicago, Illinois). All data were analyzed by a
rofessional statistician.
Figure 1 CONSORT Diagram of the Study
BMS  bare-metal stents; CONSORT  Consolidated Standards of Reporting Trialesults
aseline characteristics. Over a 30-month enrollment pe-
iod, 423 patients with acute MI were screened. Of these,
20 were randomly assigned to 1 of the 2 treatment groups:
60 to SES and 160 to BMS. A total of 103 patients were
xcluded because they had left main disease (n  3), graft
isease (n  15), or cardiogenic shock (n  32), presented
ore than 12 h after the onset of pain (n  34), or
efused to give informed consent (n  19) (Fig. 1). The
groups were well matched (Table 1). However, a higher
ercentage of patients in the BMS group had a previous
I (5.6% vs. 12.5%; p  0.047). Angioplasty was
erformed with thrombolysis in 17.8% of the patients and
ithout in 82.2% (Table 1).
rocedural results. The procedural results are summarized
n Table 2. Two patients randomized to the SES group had
ortuous calcific vessels that prevented implantation of the
ES. Both patients received a new-generation BMS
 sirolimus-eluting stents.s; SES
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May 15, 2007:1924–30 SES Versus BMS in Acute MIDriver, Medtronic, Fridley, Minnesota) but were analyzed
ith the SES group according to the intent-to-treat prin-
iple. The rate of success according to angiographic criteria
20% residual stenosis, TIMI flow grade 2 or 3) was
imilar in the 2 groups: 98.1% (SES) and 98.8% (BMS)
p  0.47). Total stent length was significantly greater in
he SES group. Stent diameter, however, was significantly
arger in the BMS group.
ngiographic results. The binary restenosis rate at 1 year
as 56% lower in the SES group than in the BMS group
9.3% vs. 21.3%, respectively; p  0.032) (Table 3).
isk factor and treatment effect analysis. No significant
reatment interactions were detected that would suggest a
ack of clinical benefit of SES in subsets of patients,
ncluding those with diabetes mellitus or variations in vessel
Baseline Characteristics of the SES Study Patie
Table 1 Baseline Characteristics of the SES
Characteristic SES (
Age (yrs)
Median
Interquartile range 5
Male gender 128
Diabetes mellitus 28
Hypertension 87
Current smoker 91
Prior myocardial infarction 9
Prior PTCA 15
Prior coronary bypass 1
Killip class 2 13
ST-segment elevation 157
PTCA only 132
PTCA  thrombolysis 28
Time from symptom onset to PTCA (h)
PTCA only
Median
Interquartile range
PTCA  thrombolysis
Median
Interquartile range 2
Angiographic features
Single-vessel disease 94
Double-vessel disease 41
Triple-vessel disease 25
Infarct-related vessel
Left anterior descending artery 75
Left circumflex artery 21
Right coronary artery 64
Enzymes
CK-MB (peak)
Median 1
Interquartile range 6
Troponin I (peak)
Median
Interquartile range 1
Data are presented as number (%), median, or interquartile range.
BMS  bare-metal stent; CK-MB  creatine kinase-myocardial bandiameter or lesion length. lajor adverse cardiac events. In-hospital adverse events
ere infrequent, with no significant difference between groups
Table 4). In-hospital death occurred in 4 BMS patients and 1
ES patient (2.5% vs. 0.6%, respectively; p  0.375). Two
atients (1.2%) in each group had a reinfarction. Angiographi-
ally documented stent thrombosis occurred in 1 BMS patient
nd 2 SES patients. There was no statistical difference in the
ombined outcome of death and MI between the 2 groups.
irolimus-eluting stent implantation resulted in reductions of
1% in TLR (4.3% vs. 11.2%; p 0.02), 62% in TVR (5% vs.
3.1%; p  0.015), 59% in MACE (6.8% vs. 16.8%; p 
.005), and 53% in TVF (8.7% vs. 18.7%; p 0.007) (Fig. 2).
iscussion
his study shows that use of SES resulted in a significantly
nd BMS Control Patients
y Patients and BMS Control Patients
60) BMS (n  160) p Value
0.81
62
52–72
128 (80%)
) 37 (23.7%) 0.13
) 98 (58.7%) 0.20
) 83 (51.7%) 0.10
) 20 (12.5%) 0.047
) 17 (10.6%) 0.38
) 1 (0.6%) 0.75
) 15 (9.3%) 0.38
) 158 (98.7%) 0.5
) 131 (81.8%) 0.53
) 29 (18.2%) 0.54
0.65
4
3–6
0.64
6.2
3.0–8.5
) 92 (57.5%) 0.92
) 42 (26.2%) 0.92
) 42 (26.2%) 0.88
) 84 (52.5%) 0.29
) 20 (12.5%) 0.54
) 56 (35.0%) 0.46
138 0.88
61–264
47.5 0.87
16–80
 percutaneous coronary angioplasty; SES  sirolimus-eluting stent.nts a
Stud
n  1
63
4–70
(80%)
(17.5%
(54.3%
(56.8%
(5.6%
(9.4%
(0.6%
(8.1%
(98.1%
(82.5%
(17.5%
4
3–7
6.0
.6–9.5
(58.7%
(25.6%
(15.6%
(46.8%
(13.1%
(40.1%
47.5
6–276
55
5–80ower rate of angiographic binary restenosis than BMS in
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SES Versus BMS in Acute MI May 15, 2007:1924–30atients with acute ST-segment elevation MI who under-
ent angioplasty with or without thrombolysis. Sirolimus-
luting stents also led to a higher rate of 1-year event-free
urvival.
These findings extend and confirm the positive finding of
ES in stable patients to patients with ST-segment eleva-
ion MI. In the STRATEGY (Single High-Dose Bolus
irofiban and Sirolimus-Eluting Stent vs. Abciximab and
are-Metal Stent in Myocardial Infarction) trial (2), 175
atients with ST-segment elevation MI were randomized to
eceive single high-dose bolus of tirofiban plus SES or
bciximab plus BMS. However, the randomization design
Procedural Results
Table 2 Procedural Results
Value SES (
Procedural success 157
No. of stents implanted
Mean
Interquartile range
Stent length (mm) 16.9
Stent diameter (mm) 3.14
Abciximab therapy
Started in emergency room 26
Started in catheterization laboratory 98
TIMI flow
PTCA only
Before procedure 28
After procedure 150
PTCA  thrombolysis
Before procedure 15
After procedure 139
Minimal lumen diameter (mm)
Before procedure
Median
Interquartile range
Final
Median
Interquartile range 2
Extent of stenosis
Before procedure
Median 1
Interquartile range 7
Final
Median
Interquartile range 4
Data are presented as number (%), mean  SD, median, or interquar
TIMI  Thrombolysis In Myocardial Infarction; other abbreviations a
ngiographic Results at 1-Year Follow-Up
Table 3 Angiographic Results at 1-Year Follow-Up
Outcome SES (n  86) BMS (n  80) p Value
Binary restenosis (%) 9.3 21.3 0.03
Angiographic occlusion (%) 2.5 3.7 0.42
Mean diameter stenosis (%) 14 34 0.001
Late luminal loss (mm) 0.18 0.85 0.001bbreviations as in Table 1. Aas primarily based on economic considerations, with the
ope that the lower cost of tirofiban would offset the cost of
ES, and binary stent restenosis was not the primary end
oint, which it was in our study.
60) BMS (n  160) p Value
158 (98.8) 0.47
1
1–1
19.4  4.8 0.001
4 3.02  0.28 0.001
) 34 (21.2%) 0.25
) 84 (52.5%) 0.32
) 31 (19.3%) 0.75
) 137 (85.6%) 0.40
) 42 (26.2%) 0.16
) 137 (85.6%) 0.89
0.38
0
0–7
0.41
2.7
5 2.4–2.90
0.45
100
72.1–100
0.14
8.9
3 4.5–16.1
ge.
le 1.
linical Outcome at Hospital Discharge and at 1 Year
Table 4 Clinical Outcome at Hospital Discharge and at 1 Year
Outcome SES BMS p Value
At hospital discharge
Death (%) 1 (0.6%) 4 (2.5%) 0.19
Reinfarction (%) 2 (1.2%) 2 (1.2%)
Target vessel revascularization (%) 1 (0.6%) 1 (0.6%)
At 1 yr
Death (%) 3 (1.8%) 7 (4.3%) 0.36
Reinfarction (%) 3 (1.8%) 3 (1.8%)
Stent thrombosis (%)
Definite 2 (1.2%) 1 (0.6%)
Probable/possible 5 (3.1%) 6 (3.7%) 0.43
Target lesion revascularization 7 (4.3%) 18 (11.2%) 0.02
Target vessel revascularization 8 (5.0%) 22 (13.1%) 0.015
Major adverse coronary events 11 (6.8%) 27 (16.8%) 0.005
Target vessel failure 13 (8.7%) 29 (18.7%) 0.007n  1
(98.1)
1
1–1
 4.1
 .03
(16.2%
(61.2%
(17.5%
(93.8%
(9.4%
(83.9%
0
0–7
2.7
.4–2.9
00
3–100
10.5
.1–18.bbreviations as in Table 1.
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May 15, 2007:1924–30 SES Versus BMS in Acute MIRecently, 2 randomized trials specifically studied the efficacy
nd safety of SES and paclitaxel-eluting stents in patients with
cute MI. In TYPHOON (Trial to Assess the Use of the
ypher Stent in Acute Myocardial Infarction Treatment With
alloon Angioplasty) (17), the rate of repeated revasculariza-
ion procedures was significantly lower in the SES group than
n the BMS control group. In the PASSION (Paclitaxel-
luting Stent versus Conventional Stent in Myocardial Infarc-
ion With ST-Segment Elevation) trial (18), the reduction in
he need for TLR with paclitaxel-eluting stents did not reach
tatistical significance.
The present study was designed to ascertain whether an
ES is associated with a significantly lower rate of binary
estenosis (our primary end point) compared with BMS. In
ontrast, the primary end points were TVF in the
YPHOON trial and MACE in the PASSION trial. In
he present study, restenosis was evaluated angiographically
t 1 year in all 160 prespecified patients required by power
alculation. Angiographic follow-up was performed at 8
onths in the TYPHOON trial and was not performed in
he PASSION trial. In addition, the inclusion criteria were
roader in the present study than in the TYPHOON trial,
hich excluded patients who had a previous MI, received a
brinolytic agent for the index infarction, had an ejection
raction 30%, or had ostial, bifurcation, or excessively
ortuous lesions. Therefore, the present results in the
ESAMI trial confirm and extend the findings of the
Figure 2 Actuarial Rate of Survival Free From TLR and TVF
Among Patients Who Received an SES or a BMS
The rate of event-free survival was significantly higher in the sirolimus-eluting
stent (SES) group. BMS  bare-metal stent; TLR  target lesion revasculariza-
tion; TVF  target vessel failure.YPHOON trial, showing that SES markedly reduces tlinical events at 1-year follow-up, primarily because fewer
epeated revascularization procedures are required.
Although significantly lower than in the BMS group, the
ncidence of angiographically confirmed binary restenosis in
he SES group was not negligible (9.3%). Saia et al. (19)
eported a binary restenosis rate of 0% in patients with
T-segment elevation MI. However, the difference may
eflect, in part, the shorter angiographic follow-up time (6
onths) in that study. The incidence of angiographic
estenosis in the BMS arm (21.3%) was comparable with
hat in other studies (11,14,20).
Although efficacy in reducing restenosis has been dem-
nstrated, the safety of SES in the setting of acute MI had
ot been resolved. Laboratory data suggested that SES
ould induce endothelial dysfunction (21), delay vascular
ealing (22), and increase agonist-induced platelet aggrega-
ion (23), potentially resulting in greater risk of stent
hrombosis than with BMS. In a clinical study, vessel
egments adjacent to SES showed paradoxic exercise-
nduced coronary vasoconstriction, a sign of dysfunctional
ndothelium (24). In a postmortem study, several proce-
ural and pathologic risk factors for stent thrombosis were
dentified, such as a local hypersensitivity reaction, ostial or
ifurcation stenting, malapposition or incomplete apposi-
ion, restenosis, and strut penetration into a necrotic core
25). Meanwhile, in a prospective observational cohort study
f 2,229 consecutive “real-world” patients who underwent
uccessful implantation of SES or paclitaxel-eluting stents,
he cumulative incidence of stent thrombosis at 9 months
as substantially higher than the rate reported in clinical
rials (26). Premature discontinuation of antiplatelet ther-
py, renal failure, bifurcation lesions, diabetes, and low
jection fraction were identified as predictors of thrombotic
vents; all of these potentially increase the risk of throm-
otic complications and worsen the outcome after SES
mplantation, especially in vulnerable patients such as those
reated during the acute phase of MI.
In the present study, such concerns did not translate into
linical events. Using the new Academic Research Consor-
ium definitions for thrombosis, we identified only 2 epi-
odes of definite stent thrombosis in the SES group. One
pisode occurred 20 h after the procedure in a patient with
leeding problems who could not receive abciximab. The
ther occurred 8 months after the index procedure. This low
ncidence of stent thrombosis confirms the safety of SES in
he setting of acute MI reported in a large registry study, in
hich the cumulative incidence of stent thrombosis was
.87% at 1 year (27). However, that study did not have
ufficient power to detect a difference in stent thrombosis
ates between the 2 stents. In addition, although the low
ate of angiographically proven stent thrombosis in the
resent study might appear reassuring, larger dedicated
tudies with a long-term follow-up are needed to answer
his question definitively. Furthermore, the role of long-
erm dual antiplatelet therapy in patients with acute MI
reated with DES remains to be defined.
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SES Versus BMS in Acute MI May 15, 2007:1924–30tudy limitations. Several potential limitations of our
tudy should be mentioned. First, 20% of screened pa-
ients were excluded because of cardiogenic shock, left main
oronary disease, and bypass grafts. However, these exclu-
ions reflect the daily practice in the real world of interven-
ional cardiology. Second, although the angiographic read-
rs were blinded to the type of stent implanted, an
ndependent core-lab analysis would have been preferable.
hird, although we found no differences in the rates of
eath, MI, or stent thrombosis, the study did not have
ufficient power to show a difference in those clinical events.
o do so would require a study of thousands of patients,
hich would not be feasible in a small, single-center study
uch as ours. Fourth, the BMS used in the control group
as a BX stent, not a new-generation stent. However, using
stents based on the same platform helped to reveal the
ifference in antirestenotic efficacy of the sirolimus elution.
oreover, although new-generation stents may have re-
uced the restenosis rate, as shown by Pache et al. (28), the
estenosis rate in the BMS group was not particularly high
nd was in line with previous primary angioplasty trials.
onclusions
e have demonstrated that an SES reduces the incidence of
estenosis and the secondary end points of TLR, TVR,
ACE, and TVF in a broadly selected population with
T-segment elevation MI treated with primary angioplasty.
nly 2 episodes of definite stent thrombosis occurred,
ndicating that routine SES implantation in the setting of
T-segment elevation MI is safe.
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